Version 1
: Received: 21 May 2023 / Approved: 23 May 2023 / Online: 23 May 2023 (04:45:24 CEST)
How to cite:
Jankajova, M.; Pella, D.; Zenuch, P.; Zenuchova, Z.; Toth, S.; Kalanin, P.; Fedacko, J. The role of w3 PUFFA in Patients with Metabolic Syndrome and Endothelial Dysfunction. Preprints2023, 2023051570. https://doi.org/10.20944/preprints202305.1570.v1
Jankajova, M.; Pella, D.; Zenuch, P.; Zenuchova, Z.; Toth, S.; Kalanin, P.; Fedacko, J. The role of w3 PUFFA in Patients with Metabolic Syndrome and Endothelial Dysfunction. Preprints 2023, 2023051570. https://doi.org/10.20944/preprints202305.1570.v1
Jankajova, M.; Pella, D.; Zenuch, P.; Zenuchova, Z.; Toth, S.; Kalanin, P.; Fedacko, J. The role of w3 PUFFA in Patients with Metabolic Syndrome and Endothelial Dysfunction. Preprints2023, 2023051570. https://doi.org/10.20944/preprints202305.1570.v1
APA Style
Jankajova, M., Pella, D., Zenuch, P., Zenuchova, Z., Toth, S., Kalanin, P., & Fedacko, J. (2023). The role of w3 PUFFA in Patients with Metabolic Syndrome and Endothelial Dysfunction. Preprints. https://doi.org/10.20944/preprints202305.1570.v1
Chicago/Turabian Style
Jankajova, M., Peter Kalanin and Jan Fedacko. 2023 "The role of w3 PUFFA in Patients with Metabolic Syndrome and Endothelial Dysfunction" Preprints. https://doi.org/10.20944/preprints202305.1570.v1
Abstract
Aim: Evaluation of role of supplementation of omega-3 polyunsaturated fatty acids on endothelial function in patients with metabolic syndrome.
Methods: Total of 80 patients with metabolic syndrome were enrolled to two groups. We evaluated endothelial function in subjects before and after three-month treatment with omega-3 polyunsaturated fatty acids in dose 2.4g daily (800mg 3 times a day) vs placebo. Using the Endo-PAT2000 device (Itamar Medical Ltd. Caesarea, Israel), reactive hyperemia index – a parameter of endothelial function and augmentation index– a parameter of arterial stiffness were measured. Plasmatic level of glutation peroxidase, homocysteine, apolipoprotein B and lipoprotein (a) were also evaluated.
Results: The average values of reactive hyperemia index before the treatment with n-3PUFA was 1.62 ± 0.42 , whereas 1.96 ± 0.62 at the end of the study (p<0.005). Augmentation index changed from 14.66 ± 19.55 to 9.21 ± 15.64 after the treatment (p=0.003). We also observed statistically significant decrease of apolipopotein B (0.94 ± 0.36 vs 1.13 ± 0.35, p = 0.001) and homocysteine (19.31 ± 5.29 vs. 13.78 ± 3.05, p = 0.001) and increase of the glutathion perxidase plasma levels (41.65 ± 8.90 vs. 45.20 ± 8.01), p=0.001.
Conclusion: We have observed significant improvement of the endothelial function in subjects with metabolic syndrome treated with omega-3 polyunsaturated fatty acids in dose 2.4g daily.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
